Q. Dong

发表

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Matthias Griese, P. Dřevínek, N. McElvaney, 2011, The New England journal of medicine.

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

J. Clancy, S. Freedman, F. Accurso, 2010, The New England journal of medicine.

Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data.

J. Clancy, F. van Goor, F. Accurso, 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

WS7.3 VX-661, an investigational CFTR corrector, in combination with ivacaftor, a CFTR potentiator, in patients with CF and homozygous for the F508Del-CFTR mutation: Interim analysis

J. Pilewski, S. Donaldson, M. Griese, 2013 .

Optimizing Nasal Potential Difference Analysis for CFTR Modulator Development: Assessment of Ivacaftor in CF Subjects with the G551D-CFTR Mutation

J. Clancy, F. Accurso, E. Olson, 2013, PloS one.

43 Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation

A. Quittner, J. Elborn, B. Ramsey, 2012 .

WS6.3 Measures of nutritional status in two Phase 3 trials of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR mutation

J. Elborn, B. Ramsey, Q. Dong, 2012 .

Parallel effects of VX-770 on transepithelial potential difference in vitro and in vivo

J. Clancy, F. Accurso, M. Ashlock, 2010 .

Relationship between Pulmonary outcomes, biomarkers Of CF Disease, And Serum drug Levels in Subjects with The G551D-CFTR Mutation Treated With VX-770, An Investigational Oral Potentiator Of CFTR

J. Clancy, F. Accurso, M. Ashlock, 2010, ATS 2010.

Final results of a 14- and 28-day study of VX-770 in subjects with CF

J. Clancy, S. Freedman, F. Accurso, 2009 .

Improvement in ion transport biomarkers and spirometry with the investigational CFTR potentiator VX-770 in subjects with cystic fibrosis and the G551D-CFTR mutation

J. Clancy, F. Accurso, J. Pilewski, 2010 .